-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

Benzinga·10/07/2026 14:34:04
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.